Risk Assessment of Cancer-Associated Endocrine Disorders

Abstract

Cancer-associated endocrine disorders represent a spectrum of metabolic and hormonal disturbances that frequently complicate malignancy, impacting morbidity, treatment planning, and patient outcomes. This review synthesizes current evidence on epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and management, with emphasis on recent advances and evolving guidelines. Early recognition and systematic risk assessment of cancer-associated endocrine syndromes are critical for optimizing clinical care and improving quality of life in oncology patients.

Introduction

Endocrine dysfunctions are increasingly recognized as both direct and indirect sequelae of malignancies. The interplay between tumoral biology, host metabolic responses, and oncological therapies can result in a range of endocrine disorders, from hypercalcemia to adrenal insufficiency and paraneoplastic syndromes. For clinicians, accurate risk assessment and timely intervention are vital due to the profound impact of these disorders on patient survival, therapy tolerability, and overall prognosis. This review provides a comprehensive, guideline-driven approach to understanding and managing cancer-associated endocrine disorders in the clinical setting.

Epidemiology / Disease Burden

The prevalence of endocrine complications in cancer patients varies according to tumor type, treatment modality, and patient demographics. Hypercalcemia of malignancy, for example, occurs in up to 20% of advanced cancer cases, predominantly in breast, lung, and multiple myeloma. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is reported in up to 15% of patients with small-cell lung cancer. Hypopituitarism, thyroid dysfunction, and adrenal insufficiency are emerging concerns in survivors of head and neck cancers, lymphoma, and those receiving immune checkpoint inhibitors. The burden is compounded by underdiagnosis, which can delay appropriate management and negatively affect outcomes.

Pathophysiology

Cancer-associated endocrine disorders arise from several mechanisms. Tumor cells may ectopically produce hormones or hormonally active peptides, resulting in paraneoplastic syndromes such as SIADH or ectopic Cushing’s syndrome. Direct tumor invasion or metastasis can destroy endocrine glands, while cancer therapies — notably radiotherapy, cytotoxics, and immunotherapies — can induce glandular dysfunction via inflammation, fibrosis, or autoimmune mechanisms. For instance, immune checkpoint inhibitors are linked with hypophysitis and thyroiditis, while tyrosine kinase inhibitors can disrupt thyroid hormone synthesis. Understanding these mechanisms is essential for personalized risk stratification and preventive strategies.

Risk Factors

Risk factors for developing cancer-associated endocrine disorders include primary tumor type (e.g., small-cell lung cancer for SIADH, breast cancer for hypercalcemia), extent of disease, prior irradiation or surgery involving endocrine organs, genetic predispositions, and exposure to targeted therapies or immune modulators. Patients with pre-existing endocrine disease or autoimmune backgrounds are at heightened risk, especially when receiving immune checkpoint inhibitors. Age, sex, and comorbidities further modulate individual susceptibility, necessitating tailored risk assessment protocols.

Clinical Features

Clinical manifestations vary widely and may be subtle or overlap with cancer-related symptoms. Hypercalcemia presents with neurocognitive dysfunction, constipation, polyuria, and renal impairment. SIADH is characterized by hyponatremia, confusion, and seizures. Adrenal insufficiency may manifest as fatigue, hypotension, and electrolyte imbalances, whereas thyroid dysfunctions can cause either hyper- or hypothyroid symptoms. These features often complicate the oncological clinical picture and can be misattributed to disease progression or treatment toxicity, underscoring the need for vigilance and systematic screening.

Diagnosis

Diagnosis relies on high clinical suspicion, detailed biochemical evaluation, and correlation with clinical context. Serum and urinary electrolytes, calcium, thyroid function tests, cortisol levels, and hormonal assays are central to workup. Dynamic testing, imaging (such as pituitary MRI or adrenal CT), and specific tumor markers may be indicated based on presentation. Importantly, interdisciplinary coordination between oncology and endocrinology is vital for comprehensive assessment, particularly in cases of overlapping or ambiguous symptoms.

Treatment & Management

Management strategies are guided by the underlying pathophysiology and severity of the endocrine disorder. Hypercalcemia requires aggressive intravenous hydration, bisphosphonates, and calcitonin; refractory cases may benefit from denosumab. SIADH management includes fluid restriction, hypertonic saline, and vasopressin antagonists. Hormone replacement (e.g., hydrocortisone for adrenal insufficiency, levothyroxine for hypothyroidism) is essential in glandular failure, with dose adjustments during acute illness or ongoing chemotherapy. Oncology-specific considerations, such as potential interactions with cancer therapies and the need for rapid correction prior to surgery or intensive treatment, should inform therapeutic choices.

Recent Advances / Emerging Therapies

Recent advances have reshaped the management of cancer-associated endocrine disorders. The advent of immune checkpoint inhibitors has necessitated new algorithms for the detection and management of immune-related endocrinopathies. Emerging evidence supports the use of novel agents like selective vasopressin receptor antagonists for SIADH and monoclonal antibodies for refractory hypercalcemia. Advances in molecular diagnostics, including liquid biopsy and next-generation sequencing, are enhancing early detection of paraneoplastic syndromes. Personalized medicine approaches, integrating genomics and predictive biomarkers, hold promise for proactive risk stratification and tailored surveillance.

Guideline Recommendations

Current international guidelines, including those from the American Society of Clinical Oncology (ASCO) and Endocrine Society, emphasize the importance of baseline endocrine evaluation prior to initiating cancer therapy, especially in high-risk populations. Regular monitoring of electrolyte, calcium, and hormonal profiles is recommended during treatment, with prompt endocrinology referral for abnormal findings. Patient education regarding symptom recognition and the need for timely reporting is fundamental. Multidisciplinary care pathways are advocated to ensure rapid access to specialist input and facilitate integrated management.

Conclusion

Cancer-associated endocrine disorders are clinically significant and often underrecognized complications that demand heightened awareness and proactive management from oncology teams. Robust risk assessment, grounded in an understanding of underlying mechanisms and patient-specific risk factors, is integral to optimizing outcomes. Advances in diagnostics and therapeutics continue to evolve, underscoring the need for ongoing education and adherence to evidence-based guidelines. Early detection and interdisciplinary collaboration remain the cornerstones of effective care for affected patients.